Name: Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples (Video) | JoVE Journal
Uploaded: 2023-01-13T14:40:00.000+00:00
Duration: 8 min 49 s
Description: Learn automated separation of cell-free DNA and circulating tumor cells from whole blood for cancer genomics. This user-friendly protocol minimizes contamination and enables high-purity extraction for downstream research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This manuscript was supported in part by the Korea Medical Device Development Fund (KMDF, Grant No. RS-2020-KD000019) and the Korea Health Industry Development Institute (KHIDI, Grant No. HI19C0521020020).

All whole blood samples were obtained from lung cancer patients. The research and analysis at Clinomics are carried out by the Cancer Genomics Research Institute, and IRB research approval by the government is led by the Asan Medical Center Institutional Review Committee (IRB NO. 2021-0802) with the IRB number registered for research at Clinomics.
1. Sample preparation
<ol>
	<li>Collect 9 mL of whole blood into an EDTA or cfDNA-stable blood collection tube.</li>
	<li>Mix well by flipping the tube up and down approximately 10 times.</li>
	<li>Store the samples at room temperature (RT; for short-term storage) or 4 &#176;C (for long-term storage). Do not freeze and thaw.</li>
</ol>
2. Device preparation
<ol>
	<li>Press the power switch to turn on the instrument. 
	NOTE: A loading screen appears on the touchpad, and the instrument is initialized. Keep hands away from the instrument during the initialization. The cartridge selection screen appears after the instrument initialization is completed.</li>
	<li>Select the sample mode to be used. Change the number of samples by pressing the arrow.</li>
</ol>
3. Device operation and sample collection
<ol>
	<li>Loading of the LBx-1 cartridge
	<ol>
		<li>Select the cartridge type on the touchscreen panel of the instrument. Change the number of samples by pressing the arrow button.</li>
		<li>Open the door of the instrument and insert all the cartridges to be used in order of the number on the cartridge holder. Make sure to correctly insert the cartridge and the cartridge holder. If the cartridge is not inserted correctly, it may cause considerable damage to the instrument.</li>
		<li>For a total of four cartridges, place the dummy cartridge in the empty space of the cartridge holder.</li>
		<li>Use the support wheel to mount the cartridge and tighten the lock nut to secure it.</li>
		<li>Close the door and press the RUN button on the touchpad screen. The instrument closes the valves on the cartridges, which takes approximately 30 s.</li>
		<li>Follow the message to open the door, remove the support wheel, and remove the valve-closed cartridge from the cartridge holder.</li>
		<li>Place the cartridge on the table and prepare to inject the whole blood sample. Pipette a maximum of 10 mL of whole blood sample using a serological pipette. 
		CAUTION: Dangers of handling blood. During the entire procedure of handling blood samples and reagents, it is important to wear a laboratory coat and laboratory gloves. The provided MSDS should be thoroughly studied by the laboratory workers.</li>
		<li>Insert the pipette tip deep into the sample inlet of the cartridge and slowly inject the whole blood sample. 
		NOTE When using more than or equal to 9 mL of whole blood sample, no phosphate buffered saline (PBS) addition is necessary. When using less than 9 mL of whole blood sample, add PBS to make the total volume to 9 mL. For example, when using 7.2 mL of whole blood, please add 1.8 mL of PBS into the sample inlet. A serological pipette or a pipette tip can be used for the injection of whole blood and PBS. When using less than 8 mL of whole blood sample, the buffy coat may not be recovered even by adding 1 mL of PBS. For gDNA prep, use 200 &#181;L of whole blood, which was separated before this step.</li>
		<li>Insert the cartridges to be used in order of the number on the cartridge holder. Use the support wheel to mount the cartridge and tighten the lock nut to secure it. Close the door and press the OK button. 
		NOTE: Plasma and buffy coat are separated from whole blood automatically, which takes approximately 30 min. 
		CAUTION Danger during operation. Opening the door or touching the instrument during high-speed rotating operations can cause serious injuries. There is also a risk of injury due to asymmetric loading of the rotor. If unusual vibrations and noises occur when the instrument starts at assisted cell enrichment or expert mode, cartridge placement may be asymmetrical. Immediately press the power key to stop and properly install the cartridge.</li>
		<li>Look for the message on the screen accompanied by an alarm sound, which appears when the separation of plasma and buffy coat is complete.</li>
		<li>Stop the alarm by opening the door or pressing the STOP button. Open the door, remove the cartridge, and place it on the table.</li>
		<li>Recover 3 mL of plasma from the plasma outlet using a 1 mL pipette tip. Recover the buffy coat of 3 mL from the buffy coat outlet using a 1 mL pipette tip.</li>
	</ol>
	</li>
	<li>Loading the LBx-2 cartridge
	<ol>
		<li>Select the cartridge name on the touchscreen panel of the instrument. Change the number of samples by pressing the arrow button.</li>
		<li>Open the door and insert the cartridges to be used in order of the number on the cartridge holder.</li>
		<li>For a total of four cartridges, place the dummy cartridge in the empty space of the cartridge holder.</li>
		<li>Use the support wheel to mount the cartridge and tighten the lock nut to secure it. Ensure to correctly insert the cartridge in the cartridge holder. If the cartridge is not inserted correctly, it may cause considerable damage to the instrument.</li>
		<li>Close the door and press the RUN button on the touchpad screen. The instrument closes the valves on the cartridge, which takes approximately 30 s.</li>
		<li>Follow the message to open the door, remove the support wheel, and remove the valve-closed cartridge from the cartridge holder and place it on the table.</li>
		<li>Place the cartridge on the table and prepare to inject the density gradient solution and the whole blood sample. Check the volume of the density gradient solution and PBS to be injected depending on the volume of the whole blood sample (Supplementary Table 1).</li>
		<li>Pipette the density gradient solution using a serological pipette. Insert the pipette tip deep into the inlet of the cartridge and slowly inject the density gradient solution.</li>
		<li>After injecting the density gradient solution, pipette the whole blood sample using a serological pipette. Insert the pipette tip deep into the sample inlet of the cartridge and slowly inject the whole blood sample. 
		NOTE: When using less than 9 mL of the whole blood sample, add PBS by referring to this table (Supplementary Table 1).</li>
		<li>Insert the cartridges to be used in order according to the number on the cartridge holder. Use the support wheel to mount the cartridge and tighten the lock nut to secure it. Close the door and press the OK button.</li>
		<li>Plasma and PBMC are separated from whole blood automatically, which takes approximately 30 min. Look for the message that appears accompanied by an alarm sound, when the separation of plasma and PBMC is complete.</li>
		<li>Stop the alarm by opening the door or pressing the STOP button. Open the door, remove the cartridge, and place it on the table.</li>
		<li>Recover 3 mL of plasma from the plasma outlet using a 1 mL pipette tip. Recover 3 mL of the PBMC from the PBMC outlet using a 1 mL pipette tip.</li>
	</ol>
	</li>
	<li>Loading the FAST-auto cartridge
	<ol>
		<li>Select the cartridge on the touch screen panel of the instrument. Change the number of samples by pressing the arrow button.</li>
		<li>Open the door and insert the cartridges to be used in order of the number on the cartridge holder. For a total of four cartridges, place the dummy cartridge in the empty space of the cartridge holder.</li>
		<li>Use the support wheel to mount the cartridge and tighten the lock nut to secure it.</li>
		<li>Close the door and press the RUN button on the touch pad screen. The instrument closes the valves on the cartridge, which takes approximately 30 s.</li>
		<li>Follow the message to open the door, remove the support wheel, and remove the valve-closed cartridge from the cartridge holder.</li>
		<li>Place the cartridge on the table and prepare to inject the PBS solution and whole blood sample. Pipette 6 mL of PBS solution using a serological pipette. Insert the pipette tip deep into the PBS inlet of the cartridge and slowly inject 6 mL of the PBS solution.</li>
		<li>After injecting the PBS solution, pipette 3 mL of whole blood or PBMC sample obtained from LBx-2 using a serological pipette, which was previously rinsed with 1% BSA to prevent sticking of the residue. Insert the pipette tip deep into the sample inlet of the cartridge and slowly inject the whole blood sample.</li>
		<li>Insert the cartridges to be used in order of the number on the cartridge holder. Use the support wheel to mount the cartridge and tighten the lock nut to secure it. Close the door and press the OK button.</li>
		<li>CTCs are enriched from whole blood automatically, which takes approximately 15 min. Look for a message that appears accompanied by an alarm sound when the enrichment of CTCs is complete. Stop the alarm by opening the door or pressing the STOP button.</li>
		<li>Open the door, remove the cartridge, and place it on the table. Insert the back plate remover (BPR) into the four holes on the front of the cartridge. Press the dark blue wing with the thumbs of both hands, and then press the light blue body until it clicks.</li>
		<li>Carefully remove the cartridge body by lifting it up. Very gently pick up the filter membrane by the edge using a tweezer. Please make sure to use the outer rim (the 1 mm wide edge part) of the filter membrane to pinch and hold the filter membrane.</li>
		<li>Carefully place the filter membrane (on which enriched CTCs are residing) into a 1.5 mL tube for nucleic acid preparation. If necessary, recover the filtered blood to the blood outlet using a 1 mL pipette tip.</li>
	</ol>
	</li>
</ol>
4. Maintenance of the system
<ol>
	<li>Preparation for cleaning and disinfection of the instrument
	<ol>
		<li>Clean all the accessible surfaces of the instrument and the accessories once a week using ethanol and dried tissue, and also immediately when contaminated.</li>
		<li>Clean the bowl and rotor shaft regularly using alcohol (ethanol and isopropanol) or alcohol-based disinfectants.</li>
	</ol>
	</li>
	<li>Cleaning and disinfecting the instrument 
	NOTE: For general troubleshooting and other notes on the machine, refer to Supplementary Table 2.
	<ol>
		<li>Switch off the instrument using the main power switch. Disconnect the power plug from the power supply.</li>
		<li>Open the door and clean and disinfect all the accessible surfaces of the instrument, including the power cable, using a damp cloth and the recommended cleaning agents.</li>
		<li>Check the rotor shaft for damage. Inspect the instrument for corrosion and damage.</li>
		<li>Connect the instrument to the power supply only if it is fully dry inside and out.</li>
	</ol>
	</li>
	<li>Disconnect the main power plug and remove the fuse holder. The fuse holder is located above the power socket. Replace the used fuse with a spare one from the container.</li>
</ol>

<ol><li>Babayan, A., Pantel, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Advances+in+liquid+biopsy+approaches+for+early+detection+and+monitoring+of+cancer%5BTitle%5D)+AND+%22Genome+Medicine%22%5BJournal%5D)">Advances in liquid biopsy approaches for early detection and monitoring of cancer.</a> Genome Medicine. 10 (1), 21(2018).</li>
<li>Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsy%3A+monitoring+cancer-genetics+in+the+blood%5BTitle%5D)+AND+%22Nature+Reviews+Clinical+Oncology%22%5BJournal%5D)">Liquid biopsy: monitoring cancer-genetics in the blood.</a> Nature Reviews Clinical Oncology. 10 (8), 472-484 (2013).</li>
<li>Bardelli, A., Pantel, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsies%2C+what+we+do+not+know+%28yet%29%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">Liquid biopsies, what we do not know (yet).</a> Cancer Cell. 31 (2), 172-179 (2017).</li>
<li>Mattox, A. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Applications+of+liquid+biopsies+for+cancer%5BTitle%5D)+AND+%22Science+Translational+Medicine%22%5BJournal%5D)">Applications of liquid biopsies for cancer.</a> Science Translational Medicine. 11 (507), (2019).</li>
<li>Heitzer, E., Perakis, S., Geigl, J. B., Speicher, M. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+potential+of+liquid+biopsies+for+the+early+detection+of+cancer%5BTitle%5D)+AND+%22NPJ+Precision+Oncology%22%5BJournal%5D)">The potential of liquid biopsies for the early detection of cancer.</a> NPJ Precision Oncology. 1 (1), 36(2017).</li>
<li>Scudellari, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Myths+that+will+not+die%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Myths that will not die.</a> Nature. 582 (7582), 322-326 (2015).</li>
<li>Prasad, V., Fojo, T., Brada, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Precision+oncology%3A+origins%2C+optimism%2C+and+potential%5BTitle%5D)+AND+%22The+Lancet+Oncology%22%5BJournal%5D)">Precision oncology: origins, optimism, and potential.</a> The Lancet Oncology. 17 (2), 81-86 (2016).</li>
<li>Prasad, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Perspective%3A+The+precision-oncology+illusion%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Perspective: The precision-oncology illusion.</a> Nature. 537 (7619), 63(2016).</li>
<li>Siravegna, G., Marsoni, S., Siena, S., Bardelli, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Integrating+liquid+biopsies+into+the+management+of+cancer%5BTitle%5D)+AND+%22Nature+Reviews+Clinical+Oncology%22%5BJournal%5D)">Integrating liquid biopsies into the management of cancer.</a> Nature Reviews Clinical Oncology. 14 (9), 531-548 (2017).</li>
<li>Bettegowda, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Detection+of+circulating+tumor+DNA+in+early-and+late-stage+human+malignancies%5BTitle%5D)+AND+%22Science+Translational+Medicine%22%5BJournal%5D)">Detection of circulating tumor DNA in early-and late-stage human malignancies.</a> Science Translational Medicine. 6 (224), 24(2014).</li>
<li>Udomruk, S., Orrapin, S., Pruksakorn, D., Chaiyawat, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Size+distribution+of+cell-free+DNA+in+oncology%5BTitle%5D)+AND+%22Critical+Reviews+in+Oncology%2FHematology%22%5BJournal%5D)">Size distribution of cell-free DNA in oncology.</a> Critical Reviews in Oncology/Hematology. 166, 103455(2021).</li>
<li>Paterlini-Brechot, P., Benali, N. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+tumor+cells+%28CTC%29+detection%3A+clinical+impact+and+future+directions%5BTitle%5D)+AND+%22Cancer+Letters%22%5BJournal%5D)">Circulating tumor cells (CTC) detection: clinical impact and future directions.</a> Cancer Letters. 253 (2), 180-204 (2007).</li>
<li>Loeian, M. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsy+using+the+nanotube-CTC-chip%3A+capture+of+invasive+CTCs+with+high+purity+using+preferential+adherence+in+breast+cancer+patients%5BTitle%5D)+AND+%22Lab+on+a+Chip%22%5BJournal%5D)">Liquid biopsy using the nanotube-CTC-chip: capture of invasive CTCs with high purity using preferential adherence in breast cancer patients.</a> Lab on a Chip. 19 (11), 1899-1915 (2019).</li>
<li>Rikkert, L. G., Van Der Pol, E., Van Leeuwen, T. G., Nieuwland, R., Coumans, F. A. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Centrifugation+affects+the+purity+of+liquid+biopsy-based+tumor+biomarkers%5BTitle%5D)+AND+%22Cytometry+Part+A%22%5BJournal%5D)">Centrifugation affects the purity of liquid biopsy-based tumor biomarkers.</a> Cytometry Part A. 93 (12), 1207-1212 (2018).</li>
<li>Sharma, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+tumor+cell+isolation%2C+culture%2C+and+downstream+molecular+analysis%5BTitle%5D)+AND+%22Biotechnology+advances%22%5BJournal%5D)">Circulating tumor cell isolation, culture, and downstream molecular analysis.</a> Biotechnology advances. 36 (4), 1063-1078 (2018).</li>
<li>Bennett, C. W., Berchem, G., Kim, Y. J., El-Khoury, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell-free+DNA+and+next-generation+sequencing+in+the+service+of+personalized+medicine+for+lung+cancer%5BTitle%5D)+AND+%22Oncotarget%22%5BJournal%5D)">Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.</a> Oncotarget. 7 (43), 71013(2016).</li>
<li>Lowes, L. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+tumor+cells+%28CTC%29+and+cell-free+DNA+%28cfDNA%29+workshop+2016%3A+scientific+opportunities+and+logistics+for+cancer+clinical+trial+incorporation%5BTitle%5D)+AND+%22International+Journal+of+Molecular+Sciences%22%5BJournal%5D)">Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation.</a> International Journal of Molecular Sciences. 17 (9), 1505(2016).</li>
<li>Bryzgunova, O. E., Konoshenko, M. Y., Laktionov, P. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Concentration+of+cell-free+DNA+in+different+tumor+types%5BTitle%5D)+AND+%22Expert+Review+of+Molecular+Diagnostics%22%5BJournal%5D)">Concentration of cell-free DNA in different tumor types.</a> Expert Review of Molecular Diagnostics. 21 (1), 63-75 (2021).</li>
<li>Park, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+tumour+cells+as+an+indicator+of+early+and+systemic+recurrence+after+surgical+resection+in+pancreatic+ductal+adenocarcinoma%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma.</a> Scientific Reports. 11 (1), 1-12 (2021).</li>
<li>Heidrich, I., Ačkar, L., Mossahebi Mohammadi, P., Pantel, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Liquid+biopsies%3A+Potential+and+challenges%5BTitle%5D)+AND+%22International+Journal+of+Cancer%22%5BJournal%5D)">Liquid biopsies: Potential and challenges.</a> International Journal of Cancer. 148 (3), 528-545 (2021).</li>
<li>Celec, P., Vlková, B., Lauková, L., Bábíčková, J., Boor, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell-free+DNA%3A+the+role+in+pathophysiology+and+as+a+biomarker+in+kidney+diseases%5BTitle%5D)+AND+%22Expert+Reviews+in+Molecular+Medicine%22%5BJournal%5D)">Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases.</a> Expert Reviews in Molecular Medicine. 20, 1(2018).</li>
<li>Thierry, A. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Origin+and+quantification+of+circulating+DNA+in+mice+with+human+colorectal+cancer+xenografts%5BTitle%5D)+AND+%22Nucleic+Acids+Research%22%5BJournal%5D)">Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.</a> Nucleic Acids Research. 38 (18), 6159-6175 (2010).</li>
<li>Moreira, V. G., de la Cera Martínez, T., Gonzalez, E. G., Garcia, B. P., Menendez, F. V. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Increase+in+and+clearance+of+cell-free+plasma+DNA+in+hemodialysis+quantified+by+real-time+PCR%5BTitle%5D)+AND+%22Clinical+Chemistry+and+Laboratory+Medicine+%28CCLM%29%22%5BJournal%5D)">Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR.</a> Clinical Chemistry and Laboratory Medicine (CCLM). 44 (12), 1410-1415 (2006).</li>
<li>Gauthier, V. J., Tyler, L. N., Mannik, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Blood+clearance+kinetics+and+liver+uptake+of+mononucleosomes+in+mice%5BTitle%5D)+AND+%22Journal+of+Immunology%22%5BJournal%5D)">Blood clearance kinetics and liver uptake of mononucleosomes in mice.</a> Journal of Immunology. 156 (3), 1151-1156 (1996).</li>
<li>Meng, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+tumor+cells+in+patients+with+breast+cancer+dormancy%5BTitle%5D)+AND+%22Clinical+Cancer+Research%22%5BJournal%5D)">Circulating tumor cells in patients with breast cancer dormancy.</a> Clinical Cancer Research. 10 (24), 8152-8162 (2004).</li>
<li>Alix-Panabières, C., Pantel, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Challenges+in+circulating+tumour+cell+research%5BTitle%5D)+AND+%22Nature+Reviews+Cancer%22%5BJournal%5D)">Challenges in circulating tumour cell research.</a> Nature Reviews Cancer. 14 (9), 623-631 (2014).</li>
<li>Zhou, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolation+of+circulating+tumor+cells+in+non-small-cell-lung-cancer+patients+using+a+multi-flow+microfluidic+channel%5BTitle%5D)+AND+%22Microsystems+%26+Nanoengineering%22%5BJournal%5D)">Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel.</a> Microsystems & Nanoengineering. 5 (1), 8(2019).</li>
<li>Sajay, B. N. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Towards+an+optimal+and+unbiased+approach+for+tumor+cell+isolation%5BTitle%5D)+AND+%22Biomedical+Microdevices%22%5BJournal%5D)">Towards an optimal and unbiased approach for tumor cell isolation.</a> Biomedical Microdevices. 15 (4), 699-709 (2013).</li>
<li>Bailey, P. C., Martin, S. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Insights+on+CTC+biology+and+clinical+impact+emerging+from+advances+in+capture+technology%5BTitle%5D)+AND+%22Cells%22%5BJournal%5D)">Insights on CTC biology and clinical impact emerging from advances in capture technology.</a> Cells. 8 (6), 553(2019).</li>
<li>Ahn, S. M., Simpson, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Body+fluid+proteomics%3A+Prospects+for+biomarker+discovery%5BTitle%5D)+AND+%22Proteomics-Clinical+Applications%22%5BJournal%5D)">Body fluid proteomics: Prospects for biomarker discovery.</a> Proteomics-Clinical Applications. 1 (9), 1004-1015 (2007).</li>
</ol>

The authors have no conflicts of interest related to this work.

The amount and concentration of cfDNA and CTC depends on the individual, stage, and type of cancer. It also depends on the condition of the patient2,4,5,10,20. In particular, in the early or precancerous stages of cancer, the concentrations of cancer-related substances are very low, so there is a high possibility that it cannot be detected. Nevertheless, early...

Early and accurate detection of various diseases, including cancer, is the most important factor in establishing a treatment strategy1,2,3,4. In particular, early detection of cancer is closely related to increased survival chances for the patient5,6,7,8. Recently, liquid biopsies have been in the spotlight for the early detection of cancer. Solid tumors undergo angiogenesis and release various substances into the blood. In particular, circulating DNAs (ctDNAs), circulating RNAs (ctRNAs), proteins, vesicles such as exosomes, and circulating tumor cells (CTCs) have been found in the blood of cancer patients2,9. Although there are differences in the amount of these substances, they are consistently observed not only in the early stages but also in the later stages6,10. However, these individual differences are very high; for example, the amount of cell-free DNA (cfDNA) containing ctDNA is less than 1,000 ng, and the number of CTCs is less than 100 in 10 mL of whole blood from cancer patients11,12,13. Many studies have characterized cancer using these substances present in lesser amounts (i.e., cfDNA, ctDNA, and CTCs). To obtain accurate results, it is important to accurately separate small amounts of substances with high purity13,14. Conventional centrifugation methods are commonly used, but they are difficult to handle and have low purity depending on the user&#39;s skill. Since the discovery of CTCs, several separation techniques have been developed, such as centrifugation or density grade separation, immunobead, and microfluidic methods. Several containment techniques have been developed since the discovery of CTCs. However, these techniques are often limited when it is necessary to isolate cells from the various chips and membranes used to isolate them15. Also, the tagging methods require equipment such as FACS, and there are limits to the downstream process due to tagging contamination.
Recently, the use of liquid biopsies have increased, and various studies are being conducted for the early detection of cancer. Although this method is simple, there are still difficulties in downstream analysis, and various studies are attempting to overcome these difficulties16,17. In addition, many sites, including hospitals, require automated, reproducible, and high-purity methods that are convenient to use. Here, we have developed a lab-on-a-disc for the automated separation of substances from blood samples following a liquid biopsy. These devices are based on the principle of centrifugation, microfluidics, and pore-sized cell capture. There are three types of discs: LBx-1 can acquire plasma and buffy coat, while LBx-2 can acquire plasma and PBMC from whole blood with a volume of less than 10 mL; FAST-auto can also acquire CTCs using a membrane that is removable from the disc. Up to four of each disc can be used in one run. Above all, the advantage of this device and method is that it can obtain a variety of cancer-derived substances from the same sample using a small amount of blood. This means that the patient&#39;s blood only needs to be drawn once. In addition, it has the advantage of excluding errors due to differences in the blood sampling period. This platform is easy to use and provides accurate results for liquid biopsies and downstream applications. In this protocol, the usage of the device and cartridge is introduced.

<table><tbody><tr><td>1% BSA (Bovine Serum Albumin)</td><td>Sigma-Aldrich</td><td>A3059</td><td></td></tr><tr><td>1.5 mL Microcentrifuge Tube</td><td>Axygen</td><td>MCT-150-C-S</td><td></td></tr><tr><td>15 mL Conical Tube</td><td>SPL</td><td>50015</td><td></td></tr><tr><td>4150 TapeStation System</td><td>Agilent</td><td>G2992AA</td><td>Cell-free DNA Screen Tape (Agilent, 5067-5630), Cell-free DNA Sample Buffer (Agilent, 5067-5633)</td></tr><tr><td>Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit&amp;nbsp;</td><td>Apostle</td><td>A17622-250</td><td>5 mL X 50 preps version</td></tr><tr><td>BD Vacutainer blood collection tubes</td><td>BD</td><td>367525</td><td>EDTA Blood Collection Tube (10 mL)</td></tr><tr><td>BioViewCCBS</td><td>Clinomics</td><td></td><td>BioView Clinomics-Customized Bioview System. Allegro Plus microscope-based customization equipment</td></tr><tr><td>CD45 Monoclonal Antibody (HI30), PE-Alexa Fluor 610</td><td>Invitrogen</td><td>MHCD4522</td><td></td></tr><tr><td>FAST Auto cartridge</td><td>Clinomics</td><td>CLX-M3001</td><td></td></tr><tr><td>LBx-1 cartridge</td><td>Clinomics</td><td>CLX-M4101</td><td></td></tr><tr><td>LBx-2 cartridge</td><td>Clinomics</td><td>CLX-M4201</td><td></td></tr><tr><td>OPR-2000 instrument</td><td>Clinomics</td><td>CLX-I2001</td><td></td></tr><tr><td>Cover Glass</td><td>Marienfeld Superior</td><td>HSU-0101040</td><td></td></tr><tr><td>DynaMag 2 Magnet Stand</td><td>Thermo Fisher Scientific</td><td>12321D</td><td></td></tr><tr><td>Ficoll Paque Solution</td><td>GE healthcare</td><td>17-1440-03</td><td>density gradient solution</td></tr><tr><td>Filter Tip, 10 &amp;micro;L</td><td>Axygen</td><td>AX-TF-10</td><td>Pipette tips with aerosol barriers are recommended to help prevent cross contamination.</td></tr><tr><td>Filter Tip, 200 &amp;micro;L</td><td>Axygen</td><td>AX-TF-200</td><td>Pipette tips with aerosol barriers are recommended to help prevent cross contamination.</td></tr><tr><td>Filter Tip, 100 &amp;micro;L</td><td>Axygen</td><td>AX-TF-100</td><td>Pipette tips with aerosol barriers are recommended to help prevent cross contamination.</td></tr><tr><td>Filter Tip, 1000 &amp;micro;L</td><td>Axygen</td><td>AX-TF-1000</td><td>Pipette tips with aerosol barriers are recommended to help prevent cross contamination.</td></tr><tr><td>FITC anti-human CD326 (EpCAM) Antibody</td><td>BioLegend</td><td>324204</td><td></td></tr><tr><td>FITC Mouse Anti-Human Cytokeratin</td><td>BD Biosciences</td><td>347653</td><td></td></tr><tr><td>Formaldehyde solution (35 wt. % in H2O)</td><td>Sigma Aldrich</td><td>433284</td><td></td></tr><tr><td>Kimtech Science Wipers</td><td>Yuhan-Kimberly</td><td>41117</td><td></td></tr><tr><td>Latex glove</td><td>Microflex</td><td>63-754</td><td></td></tr><tr><td>Magnetic Bead Separation Rack</td><td>V&amp;amp;P Scientific</td><td>VP 772F2M-2</td><td></td></tr><tr><td>Manual Pipetting&amp;nbsp; (0.5-10 &amp;micro;L)</td><td>Eppendorf</td><td>3120000020</td><td></td></tr><tr><td>Manual Pipetting&amp;nbsp; (2-20 &amp;micro;L)</td><td>Eppendorf</td><td>3120000038</td><td></td></tr><tr><td>Manual Pipetting&amp;nbsp; (10-100 &amp;micro;L)</td><td>Eppendorf</td><td>3120000046</td><td></td></tr><tr><td>Manual Pipetting&amp;nbsp; (20-200 &amp;micro;L)</td><td>Eppendorf</td><td>3120000054</td><td></td></tr><tr><td>Manual Pipetting&amp;nbsp; (100-1000 &amp;micro;L)</td><td>Eppendorf</td><td>3120000062</td><td></td></tr><tr><td>Mounting Medium With DAPI&amp;nbsp;- Aqueous, Fluoroshield</td><td>abcam</td><td>ab104139</td><td></td></tr><tr><td>Normal Human IgG Control</td><td>R&amp;amp;D Systems</td><td>1-001-A</td><td></td></tr><tr><td>OLYMPUS BX-UCB</td><td>Olympus</td><td>9217316</td><td></td></tr><tr><td>Pan Cytokeratin Monoclonal Antibody (AE1/AE3), Alexa Fluor 488</td><td>Invitrogen</td><td>53-9003-82</td><td></td></tr><tr><td>PBS (Phosphate Buffered Saline Solution)</td><td>Corning</td><td>21-040CVC</td><td></td></tr><tr><td>Portable Pipet Aid</td><td>Drummond</td><td>4-000-201</td><td></td></tr><tr><td>Slide Glass</td><td>Marienfeld Superior</td><td>HSU-1000612</td><td></td></tr><tr><td>StainTray Staining box</td><td>Simport</td><td>M920</td><td></td></tr><tr><td>Sterile Serological Pipette (10 mL)</td><td>SPL</td><td>91010</td><td></td></tr><tr><td>Triton&amp;nbsp;X-100 solution</td><td>Sigma Aldrich</td><td>93443</td><td></td></tr><tr><td>TWEEN&amp;nbsp;20</td><td>Sigma Aldrich</td><td>P7949</td><td></td></tr><tr><td>Whole Blood</td><td></td><td></td><td>Stored at 4-8 &amp;deg;C by collecting in EDTA or cfDNA stable tube : If the whole blood is insufficient in 9 mL, add PBS (phosphate buffered saline) as much as necessary.</td></tr><tr><td>X-Cite 120Q (Fluorescence Lamp Illuminator)</td><td>Excelitas</td><td>010-00157</td><td></td></tr></tbody></table>

automatic separation and collection of cancer-related substances from clinical samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Recently, liquid biopsies have been used to diagnose various diseases, including cancer. Body fluids contain many substances, including cells, proteins, and nucleic acids originating from normal tissues, but some of these substances also originate from the diseased area. The investigation and analysis of these substances in the body fluids play a pivotal role in the diagnosis of various diseases. Therefore, it is important to accurately separate the required substances, and several techniques are developed to be used for this purpose.
We have developed a lab-on-a-disc type of device and platform named CD-PRIME. This device is automated and has good results for sample contamination and sample stability. Moreover, it has advantages of a good acquisition yield, a short operation time, and high reproducibility. In addition, depending on the type of disc to be mounted, plasma containing cell-free DNA, circulating tumor cells, peripheral blood mononuclear cells, or buffy coats can be separated. Thus, the acquisition of a variety of materials present in the body fluids can be done for a variety of downstream applications, including the study of omics.

The goal of this technique is to easily and automatically isolate cancer-associated substances from whole blood. In particular, anyone can use this technique in all the suitable fields of research and analysis. The simultaneous and reproducible separation of multiple substances in a single blood sample is significant in liquid biopsies. The LBx-1 and LBx-2 discs are used for isolating plasma and buffy coat or PBMC from whole blood. Figure 1 shows the materials separated by the application of...

This paper describes the application of automated equipment to easily and efficiently separate and collect substances, such as cell-free DNA and circulating tumor cells, from whole blood.

Recently, liquid biopsies have been used to diagnose various diseases, including cancer. Body fluids contain many substances, including cells, proteins, ...

automatic-separation-collection-cancer-related-substances-from

Research

JoVE Journal

Cancer Research

Circulating tumor cells are isolated from the blood of cancer patients without inflicting cellular damage. Isolation of tumor cells is accomplished using a bimolecular surface of E-selectin in addition to antibodies against epithelial markers. A nanotube coating specifically promotes cancer cell adhesion resulting in high capture purities.

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Circulating tumor cells (CTCs) are prognostic in several metastatic cancers. This manuscript describes the gold standard CellSearch system (CSS) CTC enumeration platform and highlights common misclassification errors. In addition, two adapted protocols are described for user-defined marker characterization of CTCs and CTC enumeration in preclinical mouse models of metastasis using this technology.

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

In-depth analyses of cancer cell proteomes facilitate identification of novel drug targets and diagnostic biomarkers. We describe an experimental workflow for quantitative analysis of (phospho-)proteomes in cancer cell subpopulations derived from liquid and solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry.

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Cutaneous tumors are often discarded following Mohs micrographic surgery. A protocol is described here that enables clinical support staff to effectively process and store cutaneous tumor (e.g., squamous cell carcinoma, basal cell carcinoma, and melanoma) samples for downstream laboratory applications without interfering with clinical operations.

Establishment of a Clinic-based Biorepository

The characterization of circulating tumor cells (CTCs) is a popular topic in translational research. This protocol describes a semi-automatic immunofluorescence (IF) assay for PD-L1 characterization and enumeration of CTCs in non-small cell lung cancer (NSCLC) patient samples.

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

The manuscript presents on-site sampling of human brain tumors with solid phase microextraction followed by their biochemical profiling towards the discovery of biomarkers.

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Biobanks are crucial resources for biomedical research and the Biobank for Translational and Digital Medicine Unit at the European Institute of Oncology is a model in this field. Here, we provide a detailed description of biobanks' standard operating procedures for the management of different types of human biological samples.

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

The liquid biopsy has revolutionized our approach to oncology translational studies, with sample collection, quality, and storage being crucial steps for its successful clinical application. Here we describe a standardized and validated protocol for downstream circulating-free DNA applications that can be applied in most translational research laboratories.

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

The clinical microfluidic chip is an important biomedical analysis technique that simplifies clinical patient blood sample preprocessing and immunofluorescently stains circulating tumor cells (CTCs) in situ on the chip, allowing the rapid detection and identification of a single CTC.

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

This protocol standardizes SDS-PAGE analysis for personalized protein corona profiling on nanoparticles, enabling reproducible, scalable, and low-cost detection of cancer-specific signatures. Designed for early diagnosis of pancreatic ductal adenocarcinoma, it offers a practical, REASSURED-aligned alternative to complex proteomic methods in both research and clinical settings.

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Learn automated separation of cell-free DNA and circulating tumor cells from whole blood for cancer genomics. This user-friendly protocol minimizes contamination and enables high-purity extraction for downstream research.

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Explore More Videos